|
Mental Health Surveillance Study
|
Health Survey
|
SAMHSA
|
NIMH
|
Since 2008, the Substance Abuse and Mental Health Services Administration (SAMHSA) has produced national and state estimates of serious mental illness among adults using the National Survey on Drug Use and Health (NSDUH). The estimates are based on the Mental Health Surveillance Study (MHSS) which provides estimates of serious mental illness among adults aged 18 or older at both national and state levels. The MHSS builds upon established federal survey platforms in order to expand the NIMH research portfolio in population-based mental health studies. The purpose of the MHSS was to conduct additional calibration work on the survey data; to assess the feasibility of developing a longitudinal component for future surveys; and to produce reports related to mental health. In FY2013, NIMH participated in 23 data analysis activities related to the development of a population measure of Serious Mental Illness (SMI); mental illness correlates in adults and youth; disparities in mental health service use; suicidality in the general populations; and smoking among persons with mental illnesses.
|
|
Microphysiological Systems for Drug Efficacy and Toxicity Testing
|
Research Initiative
|
FDA
|
NCATS, NCI, NEI, NHLBI, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIGMS, NINDS, NINR, OD/DPCPSI, OD/DPCPSI/ORWH
|
The Microphysiological systems initiative aims to develop 3-D human tissue chips that accurately model the structure and function of human organs, such as the lung, liver and heart. Once developed, researchers can use these models to predict whether a candidate drug, vaccine or biologic agent is safe or toxic in humans in a faster and more cost-effective way than current methods. More than 30 percent of promising medications have failed in human clinical trials because they are determined to be toxic despite promising pre-clinical studies in animal models. These organs-on-chips will enable scientists to predict more accurately how effective a therapeutic candidate would be in clinical studies. To help streamline the therapeutic development pipeline, NIH, in collaboration with the Defense Advanced Research Projects Agency (DARPA) and the U.S. Food and Drug Administration (FDA), is leading this initiative to improve the process for predicting whether drugs will be safe in humans.
|
|
Microsystems Team
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDDK, NINDS
|
The NIH has identified a critical need for improved model systems to predict efficacy, safety, bioavailability, and toxicology outcomes for candidate therapeutics. This NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund and participating NIH IC''''s, invites applications for projects that will develop accurate cellular and organ microsystems representative of human physiology for the evaluation of drug efficacy and toxicity. By definition, these cellular and organ microsystems will have a multicellular architecture representing the characteristics and functions of the tissue of origin and will demonstrate a reproducible and viable operation under physiological conditions over a long culture period. It is anticipated that these bio-engineered human tissue models could lead to the development and commercialization of microsystems that will enable rapid and high fidelity evaluation of safety and efficacy for candidate therapeutics.
|
|
Minneapolis Somali Autism Spectrum Disorder Prevalence Project
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIEHS, NICHD, NIMH
|
Participated in working groups that provided oversight and advice to study investigators regarding analysis and dissemination plans for the study.
|
|
Mobile Applications for Data Collection on Adverse Events of Medication or Device During Public Health Emergencies
|
Resource Development
|
FDA
|
NLM
|
NLM and the U.S. Food and Drug Administration (FDA) established a partnership to explore the development, assessment, and utilization of mobile applications to disseminate and exchange scientific information and data concerning reported adverse events from the use of a medication or medical device approved under the Emergency Use Authorization in a public health emergency or disaster.
|
|
Models of Infectious Disease Agent Study (MIDAS) (RFA)
|
Research Initiative
|
CDC
|
NIGMS, FIC
|
Models of Infectious Disease Agent Study (MIDAS) is a collaboration of research and informatics groups to develop computational models of the interactions between infectious agents and their hosts, disease spread, prediction systems and response strategies. The models will be useful to policymakers, public health workers and other researchers who want to better understand and respond to emerging infectious diseases. If a disease outbreak occurs, the MIDAS network may be called upon to develop specific models to aid public officials in their decision-making processes.
|
|
mPOWER mHealth Group
|
Research Initiative
|
CDC, CMS, FDA, HRSA, IHS
|
OD/DPCPSI/OBSSR, CIT, FIC, NCCAM, NCI, NEI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NINR, NLM
|
Mobilizing Research supports the development, promotion, and dissemination of a wireless health research recruitment and data platform. In addition to being a primary data collection mechanism, the platform would be a data repository for both basic and applied health science, making validation and standardization of mobile health tools accessible.
|
|
Multi-Agency Tissue Engineering Science (MATES) Interagency Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CMS, FDA
|
NIBIB, NHLBI, NIAMS, NICHD, NIDCD, NIDCR
|
This Interagency Working Group, organized under the auspices of the Subcommittee on Biotechnology of the National Science and Technology Council (NTSC), enables Federal agencies involved in tissue engineering to stay informed of each other’s activities and coordinate efforts in a timely and efficient manner. In 2007, the Working Group published their Federal-wide strategic plan for advancing tissue science and engineering. The Working Group is formally recognized by NIH/OD as a collaborative trans-NIH working group and is actively engaged with other agencies to accelerate progress in the tissue engineering field.
|
|
Multi-Payer Claims Database
|
Resource Development
|
AHRQ, OS
|
NIA, OD/OSP
|
The goals of the Multi-Payer Claims Database (MPCD) Pilot is to evaluate the value of a multi-payer claims database for comparative effectiveness research. The database will combine public and private claims data, providing investigators with access to data on a broad patient population.
|
|
Multinational Influenza Seasonal Mortality Study (MISMS) Research
|
Research Initiative
|
OS
|
FIC, NHLBI, NIAID, NLM
|
The Multinational Influenza Seasonal Mortality Study (MISMS) was originally initiated to analyze national and global mortality patterns associated with influenza virus circulation. The focus of MISMS has since expanded to evaluate the interaction between the epidemiology, ecology, and evolutionary dynamics of influenza, including natural selection, reassortment, migration, and antigenic change. Multinational and bilateral collaborations developed by MISMS collect, analyze, and disseminate research findings through scientific publications, training workshops, and communication tools for investigators and decision-makers. Our research findings inform numerous national governments, multilateral organizations, and research stakeholders on interventions for both pandemic and seasonal influenza. To date, data have been acquired from more than 30 countries (representing ~3.2 billion people), resulting in over 100 publications.
|